News headlines about Retrophin (NASDAQ:RTRX) have trended somewhat positive on Sunday, according to AlphaOne. AlphaOne, a division of Accern, scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Retrophin earned a coverage optimism score of 0.25 on AlphaOne’s scale. AlphaOne also assigned press coverage about the biopharmaceutical company an impact score of 31 out of 100, indicating that recent media coverage is unlikely to have an impact on the company’s share price in the near future.

These are some of the media headlines that may have impacted Alpha One Sentiment’s scoring:

Insider Buying and Selling by Quarter for Retrophin (NASDAQ:RTRX)

Shares of Retrophin (NASDAQ:RTRX) traded up 1.91% during midday trading on Friday, reaching $18.10. 436,183 shares of the company’s stock were exchanged. Retrophin has a one year low of $15.55 and a one year high of $24.57. The firm’s market cap is $690.93 million. The stock’s 50-day moving average is $17.60 and its 200 day moving average is $18.98.

Retrophin (NASDAQ:RTRX) last posted its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $0.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.22) by $0.23. The business had revenue of $33.62 million during the quarter, compared to analysts’ expectations of $36.20 million. Retrophin had a negative net margin of 50.80% and a negative return on equity of 3.74%. The business’s quarterly revenue was up 15.9% on a year-over-year basis. During the same quarter last year, the company posted $0.14 earnings per share. Analysts anticipate that Retrophin will post ($1.14) EPS for the current year.

A number of equities analysts recently weighed in on the stock. BMO Capital Markets decreased their price objective on shares of Retrophin from $46.00 to $45.00 and set an “outperform” rating for the company in a report on Thursday, March 2nd. Zacks Investment Research upgraded shares of Retrophin from a “hold” rating to a “strong-buy” rating and set a $24.00 price objective for the company in a report on Tuesday, March 7th. TheStreet upgraded shares of Retrophin from a “d” rating to a “c-” rating in a report on Friday, May 12th. William Blair restated an “outperform” rating on shares of Retrophin in a report on Thursday, April 6th. Finally, ValuEngine lowered shares of Retrophin from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $32.25.

ILLEGAL ACTIVITY NOTICE: This piece was published by Financial Market News and is owned by of Financial Market News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at

Retrophin Company Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with's FREE daily email newsletter.